{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"200 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"1 Year"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Number of patients with non-relapse mortalities.","groups":[{"description":"Allogeneic Bone Marrow Transplantation: Undergo donor HCT\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant\n\nAutologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT\n\nCarmustine: Given IV\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IV\n\nEtoposide: Given IV\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative study\n\nMelphalan: Given IV\n\nMycophenolate Mofetil: Given PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo donor HCT\n\nTacrolimus: Given IV or PO\n\nTotal-Body Irradiation: Undergo TBI","id":"OG000","title":"Treatment (Autologous HCT, Donor HCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Two patients are not evaluable for GVHD due to disease progression; they failed the study and did not receive the allogeneic transplantation.","reportingStatus":"POSTED","timeFrame":"200 days and 1 Year post-allograft","title":"Non-relapse Mortality (NRM)","type":"SECONDARY","unitOfMeasure":"Participants"}